PALVELLA THERAPEUTICS, INC. - 10-Q Filing
Palvella Therapeutics filed its 10-Q for the quarter ended March 31, 2026, reporting financial results and updates following its merger with Legacy Palvella in December 2024. The filing includes unaudited condensed consolidated financial statements and details on operating losses, research and development expenses, and changes in stockholders' equity. The company also outlines its financial condition and operational results, including ongoing clinical programs for QTORIN and funding agreements.
Tickers: $PVLA